Health & Fitness

According to FutureWise analysis, the market for bioprocess containers in 2025 is US$ 5.73 billion and is expected to reach US$ 28.36 billion by 2033 at a CAGR of 22.13%. The growth in the biopharmaceutical sector is primarily due to the adoption of single-use technologies in manufacturing. Bioprocess containers are favored for their flexibility, cost-effectiveness, and lower contamination risks, making them suitable for all production scales. Furthermore, the rising development of biologics and vaccines is driving the need for scalable bioprocessing solutions. Bioprocess containers (BPCs) play a crucial role in contemporary biopharmaceutical manufacturing, functioning as specialized vessels for the safe handling, storage, and transfer of essential fluids such as cell culture media, buffers, and biologics. These containers are vital to both upstream and downstream bioprocessing workflows, facilitating the production of vaccines, monoclonal antibodies, and gene therapies within a ... Continue reading →

According to FutureWise analysis, the market for biosimilar interleukins in 2025 is US$ 4.78 billion and is expected to reach US$ 43.25 billion by 2033 at a CAGR of 31.70%. The rising prevalence of autoimmune and inflammatory diseases is driving demand for cost-effective biologic therapies. Biosimilar interleukins are gaining popularity due to their effectiveness and affordability, supported by expanding regulatory approvals. Additionally, advancements in biologics manufacturing and the expiration of key patents are creating new market opportunities. Interleukins (ILs) are essential cytokines that play a critical role in the regulation of immune responses, modulation of inflammation, and the formation of blood cells.Since the 1980s, recombinant DNA technology has enabled the therapeutic use of ILs like IL-2 (aldesleukin) for renal cell carcinoma and IL-11 (oprelvekin) for chemotherapy-induced thrombocytopenia. These biologics are complex glycoproteins requiring costly manufacturing ... Continue reading →

According to FutureWise analysis, the market for biosimilar therapeutic peptides in 2025 is US$ 3.92 billion and is expected to reach US$ 17.33 billion by 2033 at a CAGR of 20.42%. Therapeutic peptides, consisting of short chains of 2 to 50 amino acids, are designed to offer high specificity and potency in the treatment of various conditions, including diabetes, cancer, osteoporosis, and cardiovascular diseases. These peptides can be chemically synthesized or produced through recombinant methods, providing several advantages over larger biologics, such as enhanced stability, reduced immunogenicity, and precise targeting capabilities. Notable examples of therapeutic peptides include insulin, introduced in 1921, glucagon-like peptide-1 (GLP-1) agonists such as exenatide and liraglutide for managing type 2 diabetes, and teriparatide for the treatment of osteoporosis. Biosimilar therapeutic peptides are versions of originator peptides whose patents have expired. They ... Continue reading →

According to FutureWise analysis, the atopic dermatitis market in 2025 is US$8.31 billion and expected to reach US$25.47 billion by 2033 at a CAGR of 15.03%. The impressive growth of the atopic dermatitis market highlights a rising global concern, particularly among children. This increase is driven by the growing demand for effective treatment options, as families seek relief from this chronic condition. Innovative biologic therapies and targeted JAK inhibitors are at the forefront of this movement, providing greater efficacy than traditional treatments. Additionally, heightened awareness of atopic dermatitis, advancements in diagnostic capabilities, and increased healthcare spending in emerging markets are contributing to this remarkable market expansion. It is an exciting time for both patients and healthcare providers, as new solutions pave the way for better management of this condition. Atopic dermatitis, commonly known as eczema, is an inflammatory skin condition that varies in ... Continue reading →

According to FutureWise analysis, the blockchain technology in the healthcare market in 2025 is US$15.71 billion, and is expected to reach US$427.5 billion by 2033 at a CAGR of 51.13%. The blockchain technology market in healthcare is experiencing significant growth, driven by several key factors. One major factor is the increasing demand for secure patient data management, which addresses important concerns about privacy and security when handling sensitive health information. Additionally, effective interoperability solutions are becoming essential for seamless communication between various healthcare providers and systems, thereby enabling improved patient care and data sharing. Another critical issue that blockchain technology aims to address is healthcare fraud, which imposes a substantial financial burden on the industry. By providing a transparent and immutable ledger for transactions, blockchain can enhance accountability and reduce fraudulent activities related to billing and ... Continue reading →

According to FutureWise analysis, the Blood Collection Tubes for Liquid Biopsy Market in 2025 is US$0.21 billion, and is expected to reach US$0.74 billion by 2033 at a CAGR of 17.05%. The market for blood collection tubes used in liquid biopsies is experiencing significant growth, driven by several key factors. One major catalyst is the rising global incidence of cancer, which has increased the demand for innovative diagnostic solutions that facilitate early disease detection. As healthcare professionals and patients seek less invasive methods, the adoption of liquid biopsies has surged. This shift reflects a preference for non-invasive diagnostic techniques that provide critical insights without the need for traditional tissue biopsies. Technological advancements in the preservation of cell-free DNA have further boosted this market, enabling the creation of specialized collection tubes that maintain the integrity and stability of DNA samples for accurate analysis. This ... Continue reading →

According to FutureWise analysis, the botanicals and acupuncture market in 2025 is US$94.56 billion, and is expected to reach US$380.13 billion by 2033 at a CAGR of 18.99%. The botanicals and acupuncture market is experiencing significant growth, driven primarily by rising consumer preference for natural and holistic wellness solutions. This shift reflects a broader societal trend toward integrative health practices, where traditional medicine is increasingly recognized alongside conventional healthcare. As consumers become more aware of the potential side effects associated with synthetic pharmaceuticals, they are actively seeking herbal remedies and alternative therapies to manage chronic conditions such as pain, anxiety, and digestive issues. This heightened awareness is further fueled by anecdotal evidence and testimonials that highlight the effectiveness of botanical therapies. Additionally, the market is supported by favorable government policies promoting the use ... Continue reading →

According to FutureWise analysis, the cancer gene therapy market in 2025 is US$4.29 billion, and is expected to reach US$15.32 billion by 2033 at a CAGR of 17.25%. The cancer gene therapy market is currently experiencing significant growth, primarily driven by an increase in FDA approvals for innovative gene therapies and greater investments in personalized oncology treatments tailored to the unique genetic profiles of individual patients. North America currently holds a dominant position in this market, accounting for over 45% of global revenue. This dominance is due to the region's advanced healthcare infrastructure, which includes cutting-edge research facilities and a robust network of clinical practitioners, as well as high levels of research funding and a strong commitment to biopharmaceutical innovation. In contrast, the Asia-Pacific region is emerging as the fastest-growing segment of the cancer gene therapy market. This remarkable growth can be attributed to ... Continue reading →

According to FutureWise analysis, the CAR-T cell therapy market in 2025 is US$5.06 billion, and is expected to reach US$19.81 billion by 2033 at a CAGR of 18.60%. The CAR-T cell therapy market is experiencing significant growth, primarily due to an increasing number of approved CAR-T therapies that specifically target hematologic malignancies such as leukemia and lymphoma. This expansion is further supported by ongoing research aimed at developing CAR-T applications for solid tumors, which have historically posed greater challenges. One of the key factors driving market growth is the improvement of manufacturing processes. These enhancements not only reduce production timelines but also lower costs, making CAR-T therapies more accessible to a broader patient population. As more healthcare providers gain the capability to produce and administer these therapies efficiently, the availability of CAR-T treatments is expected to increase significantly. In addition to ... Continue reading →

According to FutureWise analysis, the closed system transfer devices market in 2025 is US$1.53 billion and is expected to reach US$3.02 billion by 2033 at a CAGR of 8.87%. The closed-system transfer device (CSTD) market is experiencing steady growth, primarily driven by stringent safety regulations designed to protect healthcare professionals from exposure to hazardous drugs during compounding and administration. These regulations highlight the importance of implementing effective safety measures to reduce health risks associated with cytotoxic agents. The oncology segment is the largest application area within this market, capturing a significant share due to the increasing prevalence and use of cytotoxic chemotherapy agents in cancer treatment. As the incidence of cancer grows globally, so does the demand for these medications, leading to a heightened need for robust safety measures like CSTDs to protect healthcare workers. Key end-users of CSTDs include hospital ... Continue reading →